Cardiovalve

Venus Medtech (Hangzhou) Inc. concluded its acquisition of 100% equity interest in Cardiovalve Ltd., an Israeli transcatheter mitral and tricuspid valve treatment company, on January 26, 2022.

Venus Medtech (Hangzhou) Inc. announced the acquisition of 100% equity interest in Cardiovalve Ltd., a transcatheter mitral and tricuspid valve treatment company, for a consideration of $300 million. The acquisition aims to expand Venus Medtech's product pipeline in mitral and tricuspid valve replacement.